A preclinical 2012 study led by Dr. Shuso Takeda from the Department of Molecular Biology of the Daiichi University of Pharmacy was the first to suggest that CBDA, a precursor of CBD, can be used as a potential therapy for the abrogation of aggressive breast cancers cells.